GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Devyser Diagnostics AB (OSTO:DVYSR) » Definitions » EV-to-EBIT

Devyser Diagnostics AB (OSTO:DVYSR) EV-to-EBIT : -36.59 (As of Jun. 07, 2024)


View and export this data going back to 2021. Start your Free Trial

What is Devyser Diagnostics AB EV-to-EBIT?

EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Devyser Diagnostics AB's Enterprise Value is kr1,628.3 Mil. Devyser Diagnostics AB's EBIT for the trailing twelve months (TTM) ended in Mar. 2024 was kr-44.5 Mil. Therefore, Devyser Diagnostics AB's EV-to-EBIT for today is -36.59.

The historical rank and industry rank for Devyser Diagnostics AB's EV-to-EBIT or its related term are showing as below:

OSTO:DVYSR' s EV-to-EBIT Range Over the Past 10 Years
Min: -49.58   Med: -21.04   Max: -12.95
Current: -36.59

During the past 7 years, the highest EV-to-EBIT of Devyser Diagnostics AB was -12.95. The lowest was -49.58. And the median was -21.04.

OSTO:DVYSR's EV-to-EBIT is ranked worse than
100% of 97 companies
in the Medical Diagnostics & Research industry
Industry Median: 21.36 vs OSTO:DVYSR: -36.59

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %. Devyser Diagnostics AB's Enterprise Value for the quarter that ended in Mar. 2024 was kr1,506.2 Mil. Devyser Diagnostics AB's EBIT for the trailing twelve months (TTM) ended in Mar. 2024 was kr-44.5 Mil. Devyser Diagnostics AB's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Mar. 2024 was -2.95%.


Devyser Diagnostics AB EV-to-EBIT Historical Data

The historical data trend for Devyser Diagnostics AB's EV-to-EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Devyser Diagnostics AB EV-to-EBIT Chart

Devyser Diagnostics AB Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EV-to-EBIT
Get a 7-Day Free Trial - - -46.79 -15.68 -20.37

Devyser Diagnostics AB Quarterly Data
Dec18 Dec19 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
EV-to-EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -12.57 -15.19 -13.35 -20.37 -33.85

Competitive Comparison of Devyser Diagnostics AB's EV-to-EBIT

For the Diagnostics & Research subindustry, Devyser Diagnostics AB's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Devyser Diagnostics AB's EV-to-EBIT Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Devyser Diagnostics AB's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Devyser Diagnostics AB's EV-to-EBIT falls into.



Devyser Diagnostics AB EV-to-EBIT Calculation

Devyser Diagnostics AB's EV-to-EBIT for today is calculated as:

EV-to-EBIT=Enterprise Value (Today)/EBIT (TTM)
=1628.307/-44.5
=-36.59

Devyser Diagnostics AB's current Enterprise Value is kr1,628.3 Mil.
Devyser Diagnostics AB's EBIT for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was kr-44.5 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Devyser Diagnostics AB  (OSTO:DVYSR) EV-to-EBIT Explanation

This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %.

Devyser Diagnostics AB's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Mar. 2024 is calculated as:

Earnings Yield (Joel Greenblatt) % (Q: Mar. 2024 ) =EBIT / Enterprise Value (Q: Mar. 2024 )
=-44.5/1506.17675
=-2.95 %

Devyser Diagnostics AB's Enterprise Value for the quarter that ended in Mar. 2024 was kr1,506.2 Mil.
Devyser Diagnostics AB's EBIT for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was kr-44.5 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Devyser Diagnostics AB EV-to-EBIT Related Terms

Thank you for viewing the detailed overview of Devyser Diagnostics AB's EV-to-EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.


Devyser Diagnostics AB (OSTO:DVYSR) Business Description

Traded in Other Exchanges
N/A
Address
Instrumentvagen 19, Hagersten, SWE, 126 53
Devyser Diagnostics AB is specialized in the development, manufacture and sale of market-leading genetic diagnostic kits.The products are used for complex DNA testing in the hereditary disease, oncology and post-transplantation monitoring fields, to enable targeted cancer treatment, the diagnosis of a large number of genetic diseases, and transplant patient follow-up.

Devyser Diagnostics AB (OSTO:DVYSR) Headlines

No Headlines